Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

NEW YORK – Predictive Oncology told shareholders this week that it will launch its tumor profiling assay ChemoFx in Europe and will expand commercialization in the US after securing a $10 million ...

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.

Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.